source
- GSK receives accelerated FDA approval for oral lung cancer drug neladalkibGSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
- AriBio's AR1001 shows 31% slower cognitive decline in monotherapy Phase 3 trialAriBio presented data at the 2026 Clinical Trials on Alzheimer's Disease conference indicating its candidate AR1001 slowed cognitive decline compared with placebo in patients not taking other Alzhe…